miR-223在原发性肝癌患者血清中的表达及临床意义

Expression and clinical value of serum miR-223 in hepatocellular carcinoma

目的:探讨血清中miR-223在原发性肝癌(HCC)患者血清中的表达情况。方法:选取2017年7月至2018年1月广西医科大学第一附属医院收治的50例HCC患者(HCC组),另同期选取50例健康志愿者(健康对照组)以及50例良性肝病患者(良性肝病组,包括25例乙型肝炎患者和25例乙型肝炎相关肝硬化患者)。采用实时荧光定量PCR(qPCR)法检测血清中miR-223的表达水平。分析miR-223表达与HCC患者临床病理特征的关系,并采用受试者工作特征(ROC)曲线评价血清miR-223在HCC中的诊断效能。结果:HCC组血清miR-223的表达水平显著高于健康对照组和良性肝病组,良性肝病组miR-223表达水平显著高于健康对照组,差异均有统计学意义(均P<0.05)。血清miR-223表达水平在健康对照组和良性肝病组、良性肝病组和HCC组以及健康对照组和HCC组中的ROC曲线下面积(AUC)、灵敏度和特异度分别为0.986、100.00%和90.00%,0.666、52.00%和90.00%,0.983、94.00%和96.00%。HCC患者血清miR-223的表达水平与血清AFP浓度呈正相关关系(r=0.290,P<0.05),而与性别、年龄、有无肝硬化、淋巴结转移、临床分期均无明显相关关系(均P>0.05)。结论:miR-223在HCC中呈高表达,可能成为诊断HCC的一种潜在的生物标志物。

Objective: To investigate the expression of miRNA-223 (miR-223) in the serum of hepatocellular carcinoma (HCC) patients and its clinical value. Methods: A total of 50 HCC patients,50 cases with benign liver disease (BLD) including 25 chronic hepatitis B (CHB) and 25 cirrhosis,and 50 healthy controls were selected.The expression of miR-223 was measured by real-time fluorescence quantitative PCR (qPCR).The correlation between the expression of miR-223 and clinical features of HCC patients was analyzed. Results: The expression level of miR-223 in HCC group was significantly higher than that in the BLD group and the healthy control group,and it was higher in the BLD group compared to the healthy controls ( P <0.05).The area under the ROC curve (AUC),sensitivity and specificity of serum miR-223 level in the diagnosis of HCC was 0.983,94.00% and 96.00%,respectively.The expression level of serum miR-223 in HCC patients was positively correlated with the serum AFP content ( P <0.05),but not related to gender,age,cirrhosis,lymphatic metastasis and clinical stage ( P >0.05). Conclusion: The expression of miR-223 was up-regulated in HCC patients,which might be a potential biomarkers for HCC.